Top 50 Crispr Therapy

Modalis is a biotech company that utilizes CRISPR technology to develop targeted therapeutics for genetic disorders, specifically focusing on conditions like congenital muscular dystrophy. Their approach aims to provide precise gene editing solutions to address the underlying genetic causes of these diseases.

The startup develops gene therapies using artificial intelligence to enhance the design and optimization of genetic constructs. Their technology enables researchers to create more predictable and controllable gene therapies, facilitating faster development for various applications.

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.

Brink Therapeutics develops next-generation recombinase enzymes designed for ultra-precise and efficient gene editing. These enzymes aim to enable large-scale production of cell and gene therapies for treating cancer and genetic disorders.

Scribe Therapeutics engineers CRISPR-based therapeutics to modify genetic predispositions, specifically targeting cardiometabolic diseases. By creating safe and effective gene-editing solutions, the company aims to empower individuals to take control of their health outcomes rather than being limited by inherited conditions.

Broken String Biosciences develops the INDUCE-seq® platform, a technology for characterizing genome breaks in cell and gene therapies. This platform addresses the challenge of off-target effects in CRISPR-Cas9 gene editing, enhancing the safety and efficacy of these transformative treatments.

SeQure Dx provides analytical tools that evaluate on-target specificity and off-target risks in CRISPR gene editing therapies, ensuring safety throughout the development process. By delivering precise safety data, the company addresses concerns about unintended genomic alterations that could impact patient outcomes and regulatory compliance.

The startup develops gene therapies targeting rare diseases, utilizing advanced genetic engineering techniques to create tailored therapeutic solutions. By accelerating research and enhancing global access to these therapies, the company aims to bring effective treatments from laboratory discovery to patient care more efficiently and affordably.

The startup develops optimized CRISPR guide RNA and edited cells for the cell biology and gene therapy research markets, offering products such as CRISPR reagents and gene knockout kits. Their solutions enable researchers to perform genome engineering more efficiently and reliably, facilitating advancements in genetic research and therapeutic applications.

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

The startup has developed a gene-editing technology that enables scalable digital genome engineering through a user-friendly interface. This technology produces low-cost libraries of thousands of designer protein and genome variants, each with specific and trackable mutations, facilitating efficient research and development in genetic engineering.

Prime Medicine utilizes Prime Editing, a precise gene editing technology that enables the targeted replacement of faulty DNA sequences without causing double-strand breaks. This approach aims to directly correct genetic mutations responsible for debilitating diseases, potentially offering long-lasting therapeutic benefits.

CRISPR QC Analytics Platform provides real-time quantitative insights into ribonucleoprotein (RNP) formation, DNA target binding kinetics, and cleavage activity to enhance the efficiency of CRISPR gene editing workflows. By enabling researchers to pre-screen gRNA efficiency and optimize RNP assembly, the platform reduces the time and costs associated with troubleshooting and iterative screening in gene editing experiments.

Tessera Therapeutics is pioneering Gene Writing™, a genome engineering technology that enables precise alterations to the human genome to treat genetic diseases at their source. This platform addresses the need for permanent and potentially curative therapies by delivering therapeutic genetic modifications directly to targeted tissues without the use of viral vectors.

Pencil Biosciences is developing a fully synthetic, modular gene editing technology that operates independently of CRISPR, enabling precise modulation of genetic sequences. This technology aims to provide new therapeutic options for patients with rare diseases by addressing the limitations of existing gene editing methods.

Faze Medicines is a biotechnology company focused on developing targeted therapies using advanced gene editing techniques to address genetic disorders. Their approach aims to enhance treatment precision and improve patient outcomes by directly modifying disease-causing genes.

KSQ Therapeutics utilizes its CRISPRomics® platform to identify and target the genome's most promising therapeutic candidates for curing human diseases. The company is advancing CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) programs to develop effective treatments for cancer.

The startup develops genetic medicines utilizing genome editing and engineering techniques to create pharmaceutical and biological preparations for human therapeutics. This approach enables researchers to effectively target and modify genetic disorders, improving treatment outcomes for patients.

CorriXR Therapeutics utilizes a CRISPR/Cas gene editing platform to disable drug resistance genes in tumor cells, specifically targeting squamous cell carcinoma of the head and neck. Their lipid nanoparticle delivery system minimizes off-target effects, enhancing the efficacy of cancer treatments.

The company develops genome editing-based therapies for genetic disorders, oncology, and organ transplants. Their technology enables precise genetic recombination to create off-the-shelf treatments for previously incurable diseases.

Twelve Bio develops CRISPR-Cas12a diagnostic technology that enables precise detection and modification of DNA sequences. This technology addresses the need for accurate genetic diagnostics and targeted gene editing to treat genetic disorders and diseases.

Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.

This startup provides bioinformatics solutions for drug discovery and development, focusing on personalized and precision therapies. Their services include CRISPR/siRNA selection, customized reference genomes, target discovery, and mechanism of action identification, helping healthcare firms accelerate drug development for cancers and rare diseases.

This startup is operating in stealth mode and no information is available.

The startup develops gene editing therapeutics that target and disrupt viral genes associated with neurotrophic viruses, transforming them into safe and effective treatments. This enables healthcare providers to effectively manage diseases caused by viral infections, improving patient outcomes.

Editpep develops a class of peptides designed to deliver CRISPR enzymes effectively, enhancing the precision of gene editing applications. This technology addresses the challenge of efficient and targeted delivery in CRISPR therapies, improving the potential for therapeutic outcomes.

InnoSkel is a biotechnology company developing targeted gene therapies for rare skeletal diseases, utilizing advanced CRISPR technology to correct genetic mutations. Their approach aims to improve patient outcomes by addressing the underlying genetic causes of these conditions, which currently lack effective treatment options.

Algen Biotechnologies utilizes a proprietary CRISPR gene-modulation system and advanced AI models to decode complex gene networks and identify disease-driving RNA signaling pathways. This approach accelerates therapeutic drug discovery by providing high-confidence insights into the biological mechanisms underlying various diseases.

Acrigen Biosciences develops precision gene editing systems utilizing proprietary αCas and μCas CRISPR-Cas nucleases paired with engineered anti-CRISPR proteins to enhance the accuracy and safety of genetic therapies. The company aims to address genetic disorders by providing targeted and efficient gene editing solutions for human therapeutics.

This biotechnology company develops protein-based genome editors designed for therapeutic applications in oncology and other disease areas. Their technology provides healthcare organizations with enzymes that exhibit high cell permeability and editing efficiency, addressing the need for more effective treatment options.

CrisprBits utilizes CRISPR gene-editing technology to develop affordable diagnostics and therapeutics for infectious and inherited diseases, as well as cancer. The company focuses on creating next-generation CAR-T cells and disease tissue models from edited induced pluripotent stem cells, addressing critical healthcare needs in India.

The startup develops genome editing technology that enables the cultivation of bacteria to modify and control microbiomes for therapeutic applications. This approach allows researchers to conduct precise gene editing and microbiome engineering, facilitating the development of targeted treatments for various health conditions.

The startup develops a microfluidics chip that enables non-viral transfection for CRISPR screening at single donor resolution, requiring 100 times less input material. This technology significantly reduces the time and cost of drug discovery workflows by enhancing lab automation through miniaturization and parallelization.

The startup develops gene therapies utilizing a biocompatible delivery system to facilitate targeted treatment of genetic diseases. This approach enhances the efficacy of therapeutic interventions, addressing the limitations of traditional treatment methods in the biotechnological market.

The startup specializes in precision genetic therapies that modulate neural activity to treat various neurological disorders. By utilizing targeted gene editing techniques, it aims to improve patient outcomes in conditions such as epilepsy and neurodegenerative diseases.

C4U Corporation specializes in the research and development of gene editing technologies, focusing on CRISPR-based methods to precisely modify genetic sequences. The company aims to address genetic disorders and enhance agricultural traits, providing targeted solutions for health and food security challenges.

HuidaGene Biotechnology Co., Ltd develops CRISPR-based gene-editing tools and therapies targeting genetic disorders in ophthalmology, neurology, and neuromuscular diseases. Their technology aims to repair genetic mutations responsible for life-threatening conditions, such as Duchenne Muscular Dystrophy and inherited retinal dystrophies.

Reforgene Medicine utilizes gene editing and genomic technology to develop curative therapies for genetic diseases, specifically targeting conditions like thalassemia and Usher syndrome. Their approach aims to provide lifelong cures through a single administration of gene editing treatments, addressing the significant unmet medical needs of patients suffering from these hereditary disorders.

The startup develops targeted therapeutics that utilize gene editing techniques to treat cancer, focusing on genetic alterations that conventional therapies cannot reach. This approach enables patients to receive personalized treatment options that improve their health outcomes and quality of life.

GrittGene Therapeutics is focused on developing a cure for Myotonic Dystrophy Type 2 using CRISPR technology and artificial intelligence for precise gene editing and tissue-specific delivery. By leveraging a multidisciplinary approach and a wide range of expertise, the company aims to provide effective treatments that go beyond merely alleviating symptoms.

The startup provides customized genetic modeling services using CRISPR-facilitated gene targeting in embryonic stem cells to create specific mutations for research. This technology enables clients to efficiently develop knockout mice and complex genetic modifications for studying gene function and disease mechanisms.

SalioGen Therapeutics utilizes its proprietary Gene Coding™ technology to integrate large DNA sequences at specific genomic locations without the use of viral vectors or double-stranded breaks. The company focuses on developing gene therapies for inherited disorders, including Stargardt disease and cystic fibrosis, to provide potentially curative treatment options for patients.

GDMC manufactures and designs genetic medicines using advanced gene editing techniques to create targeted therapies for genetic disorders. The company addresses the need for effective treatments by providing precision medicine solutions that improve patient outcomes and reduce healthcare costs.

The startup has developed a genome editing platform that utilizes a unique toolbox for precise homologous recombination, enhancing the efficiency of gene modification. This technology addresses the limitations of traditional nuclease-based genome editing methods, enabling the creation of more effective therapeutics for human health.

This company develops gene therapies for inherited retinal diseases, delivering normal gene copies to retinal cells to correct deficits caused by mutations. Their approach aims to either replace or silence disease-causing genes, potentially restoring vision for patients with genetic blindness.

The startup develops gene therapies that target rare genetic disorders, specifically focusing on providing life-long cures for patients with rare bleeding disorders. By utilizing advanced gene editing techniques, the company aims to make these therapies both effective and affordable for those in need.

Hunterian Medicine develops a patented CRISPR delivery platform using a bidirectional promoter to efficiently package gene-editing tools within a single adeno-associated virus (AAV). This technology addresses the challenge of delivering CRISPR therapeutics for over 95% of genetic diseases that currently lack FDA-approved treatments.

Acrobat Genomics utilizes CRISPR technology and machine learning to develop high-throughput genomic solutions aimed at creating curative therapeutics for genetic disorders. The startup focuses on enhancing the precision and efficiency of gene editing, addressing the need for safe and effective genetic medicine.

The startup utilizes non-viral gene editing technology to enhance the precision and safety of cell and gene therapies. This approach addresses the limitations of traditional viral methods, reducing the risk of immune responses and improving patient outcomes.

This startup is focused on advancing scientific research for Potocki-Lupski Syndrome through the application of gene therapy techniques aimed at correcting genetic mutations. By leveraging cutting-edge medical technology, the company seeks to provide a potential treatment for this rare genetic disorder, improving patient outcomes and quality of life.